Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactopy is a probiotic dietary supplement developed by the South Korean biotechnology company Probionic. The product's primary active ingredient is the proprietary probiotic strain *Lactobacillus sakei* Probio65™, which was originally isolated from traditional Korean fermented kimchi. Lactopy is primarily positioned for the management of atopic dermatitis and the improvement of skin health through immunomodulation. The *L. sakei* Probio65 strain has been shown in clinical studies to help balance the gut microbiome and regulate immune responses, specifically by inhibiting the production of pro-inflammatory cytokines and reducing serum IgE levels. While marketed as a nutraceutical or dietary supplement, it is the subject of ongoing research into its effects on various inflammatory and metabolic conditions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Lactopy.